Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 100.00% is in line with its 5-year average of 100.00%, near the high end of its 5-year range (0.00%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 25.00% above its 12-month average of 80.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
80.00%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
100.00%
GROSS MARGIN AVG 10Y
46.34%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+25.00%
CURRENT VS 3Y AVG
0.00%
CURRENT VS 5Y AVG
0.00%
CURRENT VS 10Y AVG
+115.79%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 816 covered companies
CURRENT VS SECTOR MEDIAN
+147.65%
vs the sector median at left
Ovid Therapeutics Inc.
Market Cap
$443.27M
Gross Margin
100.00%
TTM Avg
80.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$443.46M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$437.43M
Gross Margin
0.00%
TTM Avg
-62.19%
3Y Avg
-231.05%
5Y Avg
-120.70%
Market Cap
$434.58M
Gross Margin
99.82%
TTM Avg
1.85%
3Y Avg
-144.74%
5Y Avg
-84.51%
Market Cap
$432.32M
Gross Margin
42.92%
TTM Avg
41.39%
3Y Avg
40.24%
5Y Avg
40.24%
Market Cap
$429.12M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$424.40M
Gross Margin
27.57%
TTM Avg
28.87%
3Y Avg
27.37%
5Y Avg
25.35%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | $443.27M | 100.00% | 80.00% | 100.00% | 100.00% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $443.46M | 0.00% | 0.00% | 0.00% | 0.00% |
| NeuroPace, Inc. (NPCE)vs › | $444.24M | 79.63% | 75.59% | 74.03% | 73.95% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $437.43M | 0.00% | -62.19% | -231.05% | -120.70% |
| Assembly Biosciences, Inc. (ASMB)vs › | $434.58M | 99.82% | 1.85% | -144.74% | -84.51% |
| NeoGenomics, Inc. (NEO)vs › | $432.32M | 42.92% | 41.39% | 40.24% | 40.24% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $429.12M | 0.00% | 0.00% | 0.00% | 0.00% |
| NRC Health (NRC)vs › | $458.40M | 56.33% | 58.27% | 60.30% | 61.48% |
| Tilray Brands, Inc. (TLRY)vs › | $424.40M | 27.57% | 28.87% | 27.37% | 25.35% |
| Editas Medicine, Inc. (EDIT)vs › | $423.56M | 100.00% | -208.30% | -64.13% | -41.74% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
